PPBT

Purple Biotech Ltd. is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. Headquartered in Rehovot, Israel, with operations in California, the company concentrates on oncology treatments that address unmet medical needs in hematological and solid tumor cancers. Purple Biotech's lead product candidate is CM24, a monoclonal antibody targeting CEACAM1, which is being evaluated in combination with checkpoint inhibitors for various solid tumors including pancreatic cancer and non-small cell lung cancer. The company's second candidate, NT219, is a small molecule targeting insulin receptor substrate 1 and 2 (IRS1/2), currently in Phase I/II studies for solid tumors in combination with cancer therapies. Purple Biotech emerged from the 2020 merger between Kitov Pharma and Ayala Pharmaceuticals, strategically repositioning to focus exclusively on oncology pipeline development. The company maintains collaborations with leading research institutions and cancer centers to advance its clinical programs. With a lean operational structure typical of development-stage biotechs, Purple Biotech finances its operations through equity offerings and strategic partnerships. The company trades on NASDAQ under the ticker PPBT and on the Tel Aviv Stock Exchange, providing investors access to its novel immuno-oncology platform aimed at improving outcomes for cancer patients with limited treatment options.